Unmet Needs in Management of Myeloproliferative Neoplasms

EP: 1.Myeloproliferative Neoplasms: Diagnosing Polycythemia Vera

EP: 2.Risk Stratification and Treatment Considerations in PV

EP: 3.PV Treatment Options and Dosing

EP: 4.The JAK2 Pathway in Polycythemia Vera

EP: 5.Ruxolitinib in PV: The RESPONSE Trial

EP: 6.Ruxolitinib in PV: The RESPONSE-2 Trial

EP: 7.Future Directions in the Treatment of Polycythemia Vera

EP: 8.Risk Stratification: Primary Myelofibrosis

EP: 9.Treatment Approaches for Myelofibrosis

EP: 10.Myelofibrosis: Treatment Planning and Management

EP: 11.Ruxolitinib for Myelofibrosis: Treatment Considerations

EP: 12.Selecting Therapy to Treat Myelofibrosis

Now Viewing

EP: 13.Unmet Needs in Management of Myeloproliferative Neoplasms

Pankit Vachhani, MD: There are several unmet needs in the field of myeloproliferative neoplasms [MPNs] from a therapeutic standpoint. In essential thrombocytosis, for example, where the survival is the best among all the classical forms of MPN, the current treatment options don’t particularly improve the symptomatology of the patient. So that is an unmet need for those patients. For patients with polycythemia vera or essential thrombocytosis, we also lack treatment options that could improve and modify their underlying MPN, potentially for example, decreasing their clonal evolution into, let’s say, myelofibrosis or acute myeloid leukemia. In the field of myelofibrosis, per se, there are several unmet needs, one being the improvement of overall survival in a setting of prior JAK2 inhibitor use and failure to it. In this space, which is a second-line space in myelofibrosis, we don’t have good options. Several clinical trials are ongoing to assess various new drugs in this space.

Another area of unmet need would be patients with myelofibrosis and thrombocytopenia. Thrombocytopenia, as one knows, is a risk factor for worse outcomes. But in the case of patients with myelofibrosis, and especially a platelet count of less than 50 x 109 per liter, for example, there aren’t any good treatment options. The third area of unmet need would be somewhat similar to the second point that I just mentioned, which is myelofibrosis and anemia. Anemia can sometimes prevent physicians from using the most optimal dose of JAK inhibitor that they would like. Additionally, it is a burden on the patients in the form of transfusion requirement and also more symptoms such as fatigue, dyspnea, headaches, and tiredness generally. Improving anemia therapeutically, plus or minus transfusion, would help improve the field and optimize the treatment options in the form of better dosing of JAK inhibitors or other treatment options. These are 3 areas of unmet need. Finally, if I had to choose 1 more unmet need, I would say optimizing the role of allogeneic stem cell transplant, be that through a conditioning regimen, the transplantation donor choice, or post-transplant treatment, potentially even maintenance treatment.

TRANSCRIPT EDITED FOR CLARITY